Legend Biotech Corporation
- Jurisdiction
United States - LEI
254900EIUFZTW136H859 - ISIN
US52490G1022 (LEGN )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
4
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
5
/ 7
Profile
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Read full profile
Fundamentals
- Net revenue
€680.43M - Gross margin
61.8% - EBIT
-€185.13M - EBIT margin
-27.2% - Net income
-€277.87M - Net margin
-40.8%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Earnings Calls
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Sell |
| Ray Dalio |
|
|
|
Buy |
Earnings Calls
Latest earnings call: May 13, 2024 (Q1 2024)